Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Each stock option has an exercise price per share equal to
The Compensation Committee of Protara’s Board of Directors approved the awards as an inducement material to Ms. Grendell’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com
Source: Protara Therapeutics